Amrutanjan Health Care liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

9.01×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.31×	2.31×	3.44×	4.23×	4.12×
2.02×	2.02×	3.11×	3.82×	3.66×
14.3	14.3	10.2	3.7	10.0
165	165	206	226	197

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AMRUTANJAN₹493.00

Amrutanjan Health Care Limited

· Pharma & Health

₹ CrorePeersJAGSNPHARM NGLFINE SIGACHI LINCOLN SYNCOMF THEMISMED HESTERBIOMcap ₹1,425 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	9.01
Current Ratio	4.12	4.23	3.44	2.31	2.31
Quick Ratio	3.66	3.82	3.11	2.02	2.02
Cash, Equiv & ST Investments	10.0	3.7	10.2	14.3	14.3
Working Capital	196.5	225.8	206.1	165.5	165.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.